Elemental impurities and their measurement. a: 119 Magowar Rd, Girraween 2145 p: (02) f: (02)
|
|
- Marsha Richards
- 6 years ago
- Views:
Transcription
1 Elemental impurities and their measurement
2 A change is on its way. The new millennium has brought with it a rethink of the approach to heavy metals testing in pharmaceuticals. In addition to the simple colour development method, the BP and USP now include general methods requiring individual assays of specific elements. The colour test has been used for over 100 years. It has the advantages of simplicity, reliability and ability to detect a number of analytes.
3 Are methods and <231> broken? The colour test has significant drawbacks: Which elements is it meant to control? Sample processing and evaluation is manual and takes some skill. Workup is not optimised for volatile elements. Not particularly sensitive, sensitivity differs for different elements. Limit varies for different elements because of differences in response to lead.
4 Different metals respond differently
5 BP SC IV Q. Metal Catalyst or Metal Reagent Residues Describes general approach to control of these metals Option of either a specific limit or specifications set by calculated PDE s Refers to BP Appendix VIII W for methodologies. Requirements are additional to those specified in monographs. Pharmaceutical companies are not supposed to perform extensive tests on metal residue findings of unknown sources to comply with this guideline. They may rely on general information from trustworthy suppliers.
6 SC IV Q. Classification and limits
7 BP Appendix VIII W: Determination of Metal Catalyst or Metal Reagent Residues General approach to testing. Does not provide limits or specific test methods. Includes flow charts, discusses validation and system suitability requirements. Validation required for each metal/impurity combination. Fairly prescriptive in its validation requirements specifies protocol and acceptance criteria Recovery triplicate determination at 3 concentration levels % of limit with recoveries of % for mean at each level Direct dissolution in water, organic solvent or digestion. Sealed digestion required for volatile elements.
8 BP Appendix VIII W: Determination of Metal Catalyst or Metal Reagent Residues
9 USP The first to review the heavy metals test. 3 general chapters: <232>, <233>, <2232> <232> toxicology and calculation of limits <233> test methods and validation requirements If analytical procedure of <232> is used validation is not required method includes steps which demonstrate the method performance <2232> applies to dietary supplements. <233> risk based approach, but Cd, As, Hg and Pb must be tested.
10 Harmonisation: Draft ICH Guideline Q3D: Guideline for elemental impurities Safety assessment of elemental impurities. Calculation methods for determining specification limits for ingredients or finished products from permitted daily exposure limits for each element or use set limits Classification of elemental impurities Class 1 As Cd Hg Pb toxic through all routes of administration Class 2a geologically abundant Class 2b elements which may be added to process Class 3 dependant on route of administration Class 4 low toxicity Toxicological data for 24 elements
11 Launch dates
12 Launch Dates 1 st December USP <231> replaced in all monographs by USP <233>. Method <231> will no longer appear in the USP. 2013: BP SC IV Q. Metal Catalyst or Metal Reagent Residues 5 years allowed to fully implement new BP requirements BP SC IV Q. does not apply to veterinary products
13 Analytical Procedures
14 Pros Sealed Digestion Methods Complete digestion of organic materials. (BP system suitability test: a clear solution is obtained). Suitable for volatile elements. Matrix independent. Cons Requires skilled operator and specialist knowledge. Safety risk unless manufacturers instructions followed. Low sample quantity leads to high dilution (typically x 100)
15 GFAAS ICP-OES ICP-MS 7.5 ppb Cd 10 ppb Cd
16 Instrument options GFAAS ICP-OES ICP-MS Purchase Price Running Costs Space / installation Speed of analysis Operator Training Method development Solution Volume High salt solutions LOD (typical) 10 ppb 10 ppb ppt
17 Conclusion Analysis of metal impurities is about to become much more complex. Specifications will need to be set on a case by case basis. Decisions will need to be made on the most suitable analytical technique to test to these specifications. ICP-MS may become a necessary tool in place of a test which only requires about $30 worth of glassware and a fume cupboard to carry out.
18 Acknowledgements Chemika gratefully acknowledges the supply of an ICPE OES 9000 demonstration instrument by Shimadzu Oceania.
Implementation of the ICH Q3D guideline in the Ph. Eur.
Implementation of the ICH Q3D guideline in the Ph. Eur. PQRI/USP Workshop, USP Meeting center 2-3 November 2017 Mr Bruno Spieldenner, European Pharmacopoeia, EDQM Elemental impurities in the Ph. Eur. A
More informationWhy Q3D? Elemental Impurities: Is Your Company Prepared for ICH Q3D
Elemental Impurities: Is Your Company Prepared for ICH Q3D J. Skutnik-Wilkinson VP NSF Health Sciences Pharma Biotech Q3D EWG member Quality Session 2 May 13, 2014 Why Q3D? Pharmacopoeias going in different
More informationUSP Chapters <232> and <233> Implementation Strategy. Horacio Pappa, Ph.D. Director - General Chapters U.S. Pharmacopeia
USP Chapters and Implementation Strategy Horacio Pappa, Ph.D. Director - General Chapters U.S. Pharmacopeia Chapter Heavy Metals - Issues 1. Difficulties in reproducibility Monitor solutions/standards
More informationImplementation of the ICH Q3D guideline in the Ph. Eur.
Implementation of the ICH Q3D guideline in the Ph. Eur. PQRI/USP Workshop, USP Meeting center 9-10 November 2016 Bruno Spieldenner, Ph. Eur. division, EDQM Elemental impurities in the Ph. Eur. A (r)evolution
More informationElemental Impurities Update from CVM
Elemental Impurities Update from CVM February 19, 2014 Michael Brent, Ph.D. Center for Veterinary Medicine Division of Manufacturing Technologies, HFV-146 USP and The elemental impurity limits
More informationImpact of New ICH Q3D and USP <232> Guidelines for Elemental Impurities Analyses
Impact of New ICH Q3D and USP Guidelines for Elemental Impurities Analyses Content Background... 2 Why should the amounts of elemental impurities be controlled in drug products?... 2 Regulatory requirements...
More informationElemental Impurities Regulations View from a CRO
White Paper Elemental Impurities Regulations View from a CRO Author: Alan Cross, Technical Specialist November 2016 1 www.rssl.com Abstract Regulatory control of elemental impurities in pharmaceutical
More informationDevelopment of Elemental Impurity risk assessments for existing prescription products
Development of Elemental Impurity risk assessments for existing prescription products Mark G. Schweitzer, Ph.D. Global Head, Analytical Science & Technology Novartis Technical Operations Quality 2-3 November
More informationElemental impurities impact on APIs
Regulatory Expectations on impurities in Drug Substances: Authority and Industry perspective Pavia, 2nd October 2015 Elemental impurities impact on APIs October 2 nd 2015 Annalisa Scali RegulatoryAffairsManager
More informationHow to implement ICH Q3D of elemental impurities in 5 steps
How to implement ICH Q3D of elemental impurities in 5 steps Directive ICH Q3D aims to limit the presence of potentially toxic elemental impurities (also known as heavy metals) in pharmaceutical products
More informationElementverunreinigungen in Pharmaprodukten Neue Limits und Verfahren zur Bestimmung nach USP
Elementverunreinigungen in Pharmaprodukten Neue Limits und Verfahren zur Bestimmung nach USP Ludwig Huber, Ph.D Chief Advisor, Global FDA Compliance for Ludwig Huber Phone: +49 7902 980582 E-mail: Ludwig_Huber@Labcompliance.com
More informationICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon
ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author
More informationThe European Pharmacopoeia
The European Pharmacopoeia General methods, Control of impurities, FP monographs, Pharmacopoeial harmonisation International workshop on the Chinese and the European Pharmacopoeias The new editions Dr.
More informationElemental impurities Expectations for APIs and Excipients in the EU
Elemental impurities Expectations for APIs and Excipients in the EU Implementation strategy in the European Pharmacopoeia Dr. Ulrich Rose Head of Division A European Pharmacopoeia Department EDQM 1 Elemental
More informationElemental Impurities: An Industry Perspective
Elemental Impurities: An Industry Perspective Ernest Parente, PhD Mallinckrodt Pharmaceuticals May 17, 2016 2016 GPhA CMC Workshop Overview Risk Assessment The Supplier Interface The Contractor Interface
More informationApproaches to elemental impurity product risk assessments with limited supplier information
Approaches to elemental impurity product risk assessments with limited supplier information Mark G. Schweitzer, Ph.D. Global Head, Analytical Science & Technology Novartis Technical Operations Quality
More informationHow to build a good CEP application - ICH Q3D
How to build a good CEP application - ICH Q3D Lisa Moore B.Sc. (Pharm), MPSI Pharmaceutical Assessor, HPRA, Ireland External Expert CEP assessor. The place of the Certification Procedure in the global
More informationElemental Impurities Testing at a Pharmaceutical Company
Elemental Impurities Testing at a Pharmaceutical Company Nancy Lewen Research Fellow Atomic Spectroscopy Center of Excellence Chemical and Synthetic Development Bristol-Myers Squibb PRQI-USP Workshop November
More informationElemental Impurities / Metal Impurities AFFINISOL HPMCAS (Hydroxypropyl Methylcellulose Acetate Succinate)
Effective: August 14, 2017 Supersedes: December 2, 2015 Elemental / Metal AFFINISOL HPMCAS (Hydroxypropyl Methylcellulose Acetate Succinate) USP general chapter "Elemental impurities - Limits" and
More informationImplementation of ICH Q3D in the Certification Procedure
LS/CB PUBLIC DOCUMENT (LEVEL 1) PA/PH/CEP (16) 23 Strasbourg, August 2016 Certification of suitability to the Monographs of the European Pharmacopoeia Implementation of ICH Q3D in the Certification Procedure
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationAnalysis of elemental impurities in drug products using the Thermo Scientific icap 7400 ICP-OES Duo
APPLICATION NOTE 44385 Analysis of elemental impurities in drug products using the Thermo Scientific icap 7400 ICP-OES Duo Authors Sanja Asendorf, Application Specialist, Thermo Fisher Scientific, Bremen,
More informationDietary Supplements Stakeholder Forum. Michael McGuffin, Chair Summary Discussions Wednesday, June 1, 2016
Dietary Supplements Stakeholder Forum Michael McGuffin, Chair Summary Discussions Wednesday, June 1, 2016 USP Updates and Discussions Adulterants Database Stakeholders consumers, marketers, regulators
More informationElemental Impurities and Animal Drugs An Update from CVM
Elemental Impurities and Animal Drugs An Update from CVM November 2, 2017 Michael Brent, Ph.D. Center for Veterinary Medicine (CVM) Division of Manufacturing Technologies (DMT) This presentation summarizes
More informationClass 1 Elements should be essentially absent Known or strongly suspected human toxicants Environmental hazards
BRIEFING 232 Elemental Impurities Limits, page 197 of PF 36(1) [Jan Feb 2010]. This revision to general chapter Elemental Impurities 232 is based on comments received during the public comment period.
More informationAnalysis of elemental impurities in drug products using the Thermo Scientific icap 7600 ICP-OES Duo
Analysis of elemental impurities in drug products using the Thermo Scientific icap 7600 ICP-OES Duo Grégory Lecornet, Applications Specialist, Thermo Fisher Scientific Application Note 43149 Key Words
More informationCARBOWAX SENTRY Polyethylene Glycol (PEG) and Methoxypolyethylene Glycol (MPEG) Products
Effective: June 9, 2016 Supercedes: None CARBOWAX SENTRY Polyethylene Glycol (PEG) and Methoxypolyethylene Glycol (MPEG) Products Elemental Impurities / Metal Impurities USP general chapter Elemental
More informationAgilent Resources for Workflow Compliance MEASURING ELEMENTAL IMPURITIES IN PHARMACEUTICAL MATERIALS
Agilent Resources for Workflow Compliance MEASURING ELEMENTAL IMPURITIES IN PHARMACEUTICAL MATERIALS AGILENT SOLUTIONS USP / & ICH Q3D Implementing Elemental Impurities Tests in the Pharmaceutical
More informationMulti-element determination in pharmaceutical preparations using the Thermo Scientific icap Q ICP-MS
Multi-element determination in pharmaceutical preparations using the Thermo Scientific icap Q ICP-MS Dr. Simon Nelms, Thermo Fisher Scientific, UK Application Note 43100 Key Words icap Q, Pharmaceutical
More informationICH Q3D. Questions & Answers Q1: Q2: U n d e r s ta n d i n g the Risk Assessment Requirements. Knowing the Options
ICH Q3D Questions & Answers Understanding the Risk Assessment Requirements Knowing the Options Controlling for Elemental Impurities Responsibilities U n d e r s ta n d i n g the Risk Assessment Requirements
More informationComparing an instrumental technique based on its
10 Spectroscopy 33(3) March 2018 www.spectroscopyonline.com Atomic Perspectives Choosing the Right Atomic Spectroscopic Technique for Measuring Elemental Impurities in Pharmaceuticals: A J-Value Perspective
More informationPrimary / secondary standards in pharmaceutical QC. Dr. Christian Zeine LGC Standards GmbH. Webinar Series 2013 July 2013
Primary / secondary standards in pharmaceutical QC Dr. Christian Zeine LGC Standards GmbH Webinar Series 2013 July 2013 Quick guide to the webinar tools Slide 2 Topics of today s talk Close look on: Main
More informationImpurity Control in the European Pharmacopoeia
Impurity Control in the European Pharmacopoeia Training Session Zagreb, Croatia, 24-25 May, 2018 Dr Ulrich Rose Head of Division European Pharmacopoeia Department, EDQM Agenda Which impurities are controlled?
More informationThank You to United States Pharmacopeia for Their Sponsorship and Assistance
Use of Measurement Uncertainty in Testing a Drug Substance M.L. Jane Weitzel Quality Analysis Consultants mljweitzel@msn.com Eurachem/CITAC Workshop June 2011 Thank You to United States Pharmacopeia for
More informationImage Area YOUR PRESCRIPTION FOR USP 232/233 COMPLIANCE. USP 232 / 233 Readiness Solutions and Services Overview
Image Area YOUR PRESCRIPTION FOR USP 232/233 COMPLIANCE USP 232 / 233 Readiness Solutions and Services Overview THE RIGHT DOSE OF READINESS AT JUST THE RIGHT TIME When the U.S. Pharmacopeia s (USP) new
More informationEU Regulatory Perspective and Expectations. Sven-Erik Hillver Senior expert, QWP delegate Medical Products Agency, Sweden
EU Regulatory Perspective and Expectations Sven-Erik Hillver Senior expert, QWP delegate Medical Products Agency, Sweden Disclaimer EU regulators still have to build up an experience of applications based
More informationAnalysis of Pharmaceuticals by ICP-MS and WDXRF
Analysis of Pharmaceuticals by ICP-MS and WDXRF Frank X. Weber, James M. Harrington, Andrea McWilliams, James Medlin, Keith E. Levine Trace Inorganics Department, RTI International, Research Triangle Park,
More informationDr. Jianfeng Cui, Thermo Fisher Scientific, Bremen, Germany APPLICATION NOTE AN43384
APPLICATION NOTE Using graphite furnace atomic absorption to meet the requirements of elemental impurity analysis in pharmaceutical products for arsenic, cadmium and lead Dr. Jianfeng Cui, Thermo Fisher
More informationHealth Canada's Experience When Implementing the ICH Q3D Elemental Impurity Guidance for NDSs and ANDSs
Health Canada's Experience When Implementing the ICH Q3D Elemental Impurity Guidance for NDSs and ANDSs Alison Ingham PQRI/USP Elemental Impurities workshop 9 November 2016 Introduction Health Canada is
More informationProposals for the Guideline on Classification of Variations. Only those variations applicable to the active substance are listed.
December 2008 Proposals for the Guideline on Classification of Variations Only those variations applicable to the active substance are listed. A variation which is not an extension and whose classification
More informationLhasa Limited Collaborative Data & Knowledge Sharing
Lhasa Limited Collaborative Data & Knowledge Sharing Featuring: Elemental Impurities and PDE/AI Data Sharing Dr Liz Covey-Crump liz.covey-crump@lhasalimited.org Acknowledgements: Dr Crina Heghes, Dr Will
More informationá232ñ ELEMENTAL IMPURITIES LIMITS
First Supplement to USP 40 NF 35 Chemical Tests / á232ñ al Impurities Limits 8065 Standard Solution Table 10 (Continued) of Neu5Ac after Labeling (mm) of Neu5Gc after Labeling (mm) 4 0.2 0.01 5 0.4 0.02
More informationInstitute for Reference Materials and Measurements Community Reference Laboratory for Feed Additives
EUROPEAN COMMISSION JOINT RESEARCH CENTRE Institute for Reference Materials and Measurements Community Reference Laboratory for Feed Additives D08/FSQ/CVH/GS/D(2007) 18417 CRL Evaluation Report on the
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationCase study 2: Parenteral Drug Product
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 Purpose of Case Study 2: The following case study provides one example of a summary of an elemental impurities risk
More informationDirect Analysis of Photoresist by ICP-MS. Featuring the Agilent Technologies 7500s ICP-MS
Direct Analysis of Photoresist by ICP-MS Featuring the Agilent Technologies 7500s ICP-MS 1 Presentation Outline How is photoresist used? Analytical challenges Instrumentation developments Analytical approach
More informationRegulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
More informationIndustry Consortium CB4REACH. Information Letter 3
CB4REACH Industry Consortium CB4REACH Information Letter 3 November 2009 Dear SIEF member, After receiving replies to our second SIEF Information Letter various questions were raised and clarification
More informationPQRI/USP Workshop on Implementation Status of ICH Q3D Elemental Impurity Requirements
PQRI/USP Workshop on Implementation Status of ICH Q3D Elemental Impurity Requirements Facilitators: Breakout Session #: IV Preparing for Existing Drug Product Implementation Phyllis Walsh Neil Schwarzwalder
More informationAn Alternative Approach to Quantitative Methods: Limit test for Analysis of Deeming Analytes in Electronic Cigarettes
An Alternative Approach to Quantitative Methods: Limit test for Analysis of Deeming Analytes in Electronic Cigarettes Carl Adams, Salem Chouchane and Darius Grissom www.eurofinslancasterlabs.com Questions
More informationFunctionality. Normal Operation
Application Note Automating EPA Method 200.8 using the SDXHPLD High Performance Liquid Dilution System Jim Maximovich, Teledyne CETAC Technologies, Omaha, NE, USA, Jim.Maximovich@Teledyne.com The SDX HPLD
More informationPurification, Purity Analysis, and Impurity Analysis Solutions. for Pharmaceutical Research and Development
Purification, Purity Analysis, and Impurity Analysis Solutions for Pharmaceutical Research and Development Realize Effective Pharmaceuticals The current environment within the pharmaceutical industry an
More information1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country
1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country S no 1. Name of Applicant with address 2. Name of Drug 3. Therapeutic Class 4. Date of Approval Documents
More informationImplementation of ICH Q3D in the Certification Procedure
Implementation of ICH Q3D in the Certification Procedure PQRI/USP Workshop on ICH Q3D Elemental Impurities Requirements Recent Experience and Plans for Full Implementation in 2018 November 2-3, 2017 Cristian
More informationICH Guidelines Elemental Impurities: Strategies for Implementation for APIs
ICH Guidelines Elemental Impurities: Strategies for Implementation for APIs Frankfurt, October 2017 Dr. Landry Le Chevanton 1 ICH Guidelines Elemental Impurities: Strategies for Implementation for APIs
More information[Insert name of product/s covered by the protocol]
[Insert name of product/s covered by the protocol] WRITTEN: CHECKED: Signature: Position: Date: AUTHORISED TO PROCEED: Signature: Position: Date: Insert name of transferring site Insert name of receiving
More informationOverview of Impurities
Overview of Impurities Regulatory and GMP aspects presented by Dr Clive Simon The SPD Company 2 September 2014 Definition Substances that provide no therapeutic benefit but have potential to cause adverse
More informationPHARMA KNOWLEDGE PARK
GUIDELINES 2013 WWW.NOORMD.COM A COMPILATION BY ON PHARMACEUTICAL REGULATORY GUIDELINES INTRODUCED / REVISED DURING THE YEAR 2013. Page 2 ICH Assessment and control of DNA reactive (mutagenic) impurities
More informationEMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016
EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems Jan Thomsen Warsaw, November 15 th, 2016 2 Content Emprove - An Introduction Emprove for Raw and Starting Materials
More informationValidation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness
Validation/Verification of Test Methods An FDA Perspective Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness FD & C Act Overview Definition of drugs What cgmps are Finished Pharmaceuticals cgmp
More informationAPI Stability Protocols and. Chris Byrne Tasmanian Alkaloids
API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood
More informationBRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.
Page 1 of 13 BRIEFING 1086 USP 37 page 828. As part of an ongoing monograph modernization initiative, the United States Pharmacopeial Convention (USP) is updating this general chapter, 1086 Impurities
More informationCURRENT CHALLENGES IN GLOBAL REGULATORY COMPLIANCE QUALITY OF PHARMACEUTICAL INGREDIENTS PHARMACOPOEIAL HARMONISATION PROCESS
CURRENT CHALLENGES IN GLOBAL REGULATORY COMPLIANCE QUALITY OF PHARMACEUTICAL INGREDIENTS PHARMACOPOEIAL HARMONISATION PROCESS Dr. Vinay G Nayak President, Technical Operations Alembic Pharmaceuticals Limited
More informationThe image part with relationship ID rid4 was not found in the file. Welcome
The image part with relationship ID rid4 was not found in the file. Welcome Trace Metals Analysis: Impurity Determinations By Thomas Kozikowski Chemist, R&D at Inorganic Ventures Key Considerations What
More informationReflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances
3 July 2017 EMA/CHMP/CVMP/QWP/826771/2016 Corr. 1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Reflection paper on the requirements for
More informationAgilent Atomic Spectroscopy Solutions for Energy & Chemicals AA, MP-AES, ICP-OES, ICP-MS.
Agilent Atomic Spectroscopy Solutions for Energy & Chemicals AA, MP-AES, ICP-OES, ICP-MS. 1 Agilent Technology Leadership, the first 55 years 1957 Built components for world's first AA (as Techtron) 1971
More informationTest Report. MDL Element. Other Polymers and metals Composite material Polymers material
No.R011512542R Date: Feb. 17, 2016 Page 2 of 13 Test Method: A. Screening test by XRF spectroscopy XRF screening limits in mg/kg for regulated elements according to IEC 62321-3-1:2013. Limit of IEC 62321-3-1:2013.
More informationNO INTERFERENCE BETWEEN YOU AND BETTER THROUGHPUT. NexION 1000 ICP Mass Spectrometer. For research use only. Not for use in diagnostic procedures.
NO INTERFERENCE BETWEEN YOU AND BETTER THROUGHPUT NexION 1000 ICP Mass Spectrometer For research use only. Not for use in diagnostic procedures. 2 THE PERFECT ICP-MS SYSTEM FOR WHATEVER MODE YOU'RE IN
More informationQuality Control in the Synthesis of Atorvastatin Calcium Secondary Reference Standard Kits Help Generic Manufacturers Minimize Impurities
Quality Control in the Synthesis of Atorvastatin Calcium Secondary Reference Standard Kits Help Generic Manufacturers Minimize Impurities by Steve Lane, NSF International When patent protection for Lipitor
More informationAdopted by CHMP for release for consultation 15 December Start of public consultation 15 December 2016
1 September 2017 EMA/CHMP/ICH/809509/2016 Committee for Human Medicinal Products ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological / biological
More informationAnalytical Procedures and Methods Validation for Drugs and Biologics
Final Guidance for Industry Analytical Procedures and Methods Validation for Drugs and Biologics Analytical procedures and Method Validation June 21, 2016 Lokesh Bhattacharyya Chief, LACBRP/DBSQC OCBQ/CBER/FDA
More informationLEGAL REQUIREMENTS FOR STABILITY
BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationPHARMACEUTICAL SCIENCES - QUESTIONS AND ANSWERS
PHARMACEUTICAL SCIENCES - QUESTIONS AND ANSWERS The document PHARMACEUTICAL SCIENCES - QUESTIONS AND ANSWERS is intended to provide clarification on a number of issues that relate to Quality (e.g., Chemistry
More informationWHO guidelines on variations to a prequalified product
Annex 3 WHO guidelines on variations to a prequalified product Introduction 96 1. Background 97 1.1 Objectives 97 1.2 Scope and application 98 2. Guidance for implementation 99 2.1 s 99 2.1.1 Notifications
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON SUMMARY OF REQUIREMENTS FOR ACTIVE SUBSTANCES IN PART II OF THE DOSSIER
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 28 January 1998 CPMP/QWP/297/97 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE
More informationExcipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance
Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to
More informationAcceptable Intake (AI) and Permitted Daily Exposure (PDE) Data Sharing Project for Pharmaceutical Impurities
Acceptable Intake (AI) and Permitted Daily Exposure (PDE) Data Sharing Project for Pharmaceutical Impurities Dr. William Drewe Business Development Manager David Wilkinson Senior Data Scientist Agenda
More informationASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group
ASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group Version Description of Change Author Effective Date v 1.0 Original publication ASMF/DMF WG May 26, 2015 v 1.1 Watermark added ASMF/DMF
More informationExtending Beyond Use Dating for Compounded Preparations Webinar Q&A
Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific
More informationA Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy
A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy Nicholas Cappuccino, PhD Vice-President, Head of Quality and Scientific Affairs Dr. Reddy s Laboratories,
More informationSPECIFIC MONOGRAPHS. A Guide Through The Different Sections. Claude Coune
SPECIFIC MONOGRAPHS A Guide Through The Different Sections Claude Coune Claude Coune, EDQM, Council of Europe, All rights reserved, 2010 1 Contents of the European Pharmacopoeia: nearly 2100 monographs
More informationGUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER
RESTRICTED GUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER Since being presented to the Fortieth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2005 this
More informationExtending Beyond Use Dating for Compounded Preparations Webinar Q&A
Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific
More informationVICH Topic GL10. Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN NEW VETERINARY DRUG SUBSTANCES
European Medicines Agency Veterinary Medicines and Inspections London, 19 February 2007 Doc. Ref.EMEA/CVMP/VICH/837/99-Rev.1 VICH Topic GL10 Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN
More informationAdditional guidance on: TNsG on Data Requirements, Part A, Chapter 2, Point 4. Analytical Methods for Detection and Identification.
Additional guidance on: TNsG on Data Requirements, Part A, Chapter 2, Point 4 Analytical Methods for Detection and Identification and Part B, Chapter 2, Point 4 Methods of Identification and Analysis These
More informationicap 7000 Plus Series ICP-OES Streamlined performance and ultra-low ICP-OES detection limits for routine laboratories
icap 7000 Plus Series ICP-OES Streamlined performance and ultra-low ICP-OES detection limits for routine laboratories icap 7000 Plus Series ICP-OES Powerful multi-element performance for routine and research
More informationThe Use of BPOG Generated Extractables Data for Toxicological Assessment
The Use of BPOG Generated Extractables Data for Toxicological Assessment Sade Mokuolu, Ph.D Group Product Compliance Manager, WMFTG PDA Brazil 2017 Disclaimer This presentation is the copyright information
More informationImplementation strategy of ICH Q3D guideline
08 March 2017 EMA/CHMP/QWP/115498/2017 Committee for Medicinal Products for Human use (CHMP) Draft agreed by QWP and BWP June 2016 Adopted by CHMP for release for consultation June 2016 Start of public
More informationOn the Q&A to the Guideline for Common Technical Documents
To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare
More informationTEMPLATE FOR AN EXAMPLE METHODS VALIDATION STANDARD OPERATING PROCEDURE (SOP)
APPENDIX II TEMPLATE FOR AN EXAMPLE METHODS VALIDATION STANDARD OPERATING PROCEDURE (SOP) SOP EXAMPLE TEMPLATE 1. PURPOSE 1.1 This procedure is intended to provide general guidelines for the validation
More informationImplementation strategy of ICH Q3D guideline
1 2 3 1 July 2016 EMA/404489/2016 Committee for Medicinal Products for Human use (CHMP) 4 5 Draft Draft agreed by QWP and BWP June 2016 Adopted by CHMP for release for consultation June 2016 Start of public
More informationICH Q3D RISK ASSESSMENT: REGULATORY SUCCESS AND STANDARDIZED METHODOLOGY FOR NEW FILINGS WILLIAM STEVENS- MERCK & CO., INC.
ICH Q3D RISK ASSESSMENT: REGULATORY SUCCESS AND STANDARDIZED METHODOLOGY FOR NEW FILINGS WILLIAM STEVENS- MERCK & CO., INC. 02 November 2017 PQRI/USP Elemental Impurities Workshop Outline Review of Risk
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
Ref. Ares(2014)968036-28/03/2014 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, 28 March 2014 EudraLex
More informationOverview of comments received on 'Draft Guideline on the chemistry of active substances (veterinary) (EMA/CVMP/QWP/49477/2017)
23 October 2017 EMA/CVMP/QWP/502315/2017 Committee for Medicinal Products for Veterinary Use (CVMP) Overview of comments received on 'Draft Guideline on the chemistry of active substances (veterinary)
More informationLaboratory Reagents. for life science research.
Laboratory Reagents Research, quality control, or routine analysis whatever the field of activity, where there is a need for laboratory reagents, Thermo Fisher Scientific has a suitable product. We offer
More informationUSP Guideline on Use of Accelerated Processes for Revisions to the Food Chemicals Codex 1 Effective March 6, 2014
USP Guideline on Use of Accelerated Processes for Revisions to the Food Chemicals Codex 1 Effective March 6, 2014 Background: The Rules and Procedures of the Council of Experts (Rules) 2 specify various
More informationEudraLex. Part I1 Chapter 6: Quality Control
EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines tofor Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use Part I1 Chapter 6: Quality
More informationNSF/ANSI Standards 60, 61, and 372. B.B. Singh, NSF International, June 26, 2018
NSF/ANSI Standards 60, 61, and 372 B.B. Singh, NSF International, June 26, 2018 Agenda About NSF International NSF s Mission, Capabilities, and Services NSF/ANSI Standard 60 Health Effects for Drinking
More informationChemical Aspects of Stability Evaluation
Chemical Aspects of Stability Evaluation 8 steps to generating stability data which speaks for itself Alan Doughty Chief Chemist Pty Ltd Aim of a stability trial Obtain data which allows a definitive conclusion
More information